This dataset includes data for 71 trial participants (50 male, 21 female) with renal cell carcinoma, taking part in the single arm, phase II FASTRACK study.
Participants were recruited at sites in 7 Australian sites and 1 international site (MAASTRO), and includes data from beginning of study through to 96 month follow up. The study commenced in Aug 2016 and conducted the last patient last visit in April 2025.
Dataset includes Timepoints from baseline to 96 months follow-up, tumour imaging, disease progression and AEs. Cancer Australia demographic data
– Postcode of home of address
– Aboriginal or Torres Strait Islander status (or Ethnicity)
– Culturally and Linguistically Diverse (CALD) status: Country of Birthn Main language other than English used as the principle means of communication.
Radiotherapy quality assurance data collected includes 11 benchmarking reviews, 71 pre-RT plan review, 69 post-RT plan review, 16 MRI substudy scans (baseline, 3, 12 months), split renal function scans (baseline, 12, 24, 42, 60 months)
